AUTHORS
Lauren G Tagliaferro Epler, MD, Dongyun Yang, PhD2, Haoyue Shan, MS3, Sanjeet Dadwal, MD4, Nini Huynh5, Ming Hung Fan, LCSW6, Sherry Hite, MOT7, Haris Ali, MD8, Ahmed Aribi, MD9, Brian John Ball, MD, MS10, Peter Curtin, MD11, Alex Francisco Herrera, MD12, Salman Otoukesh, MD13, Amandeep Salhotra, MD14, Karamjeet Singh Sandhu, MD15, Guido Marcucci, MD16, Eileen Smith, MD17, Monzr M. M Al Malki, MD18, Stephen J. Forman, MD19, Ryotaro Nakamura, MD20, William Dale, MD, Ph.D21, Andrew Artz, MD,MS22
AFFILIATIONS
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
ABSTRACT
Background: Advances in reduced-intensity conditioning and donor availability have expanded the use of allogeneic hematopoietic cell transplantation (HCT). However, non-relapse mortality (NRM) among older patients remains high with minimal improvement in registry analyses; further substantial geriatric morbidity and functional loss complicate HCT recovery. We build on a prior quality program of geriatric assessment (GA) to characterize age-related vulnerabilities followed by evaluation from a multi-disciplinary team (MDT) of specialists before HCT in older adults (Derman Blood Adv 2019). We now report on the first prospective trial of comprehensive GA followed by multidisciplinary team (MDT) of six disciplines to mitigate early HCT complications through both universal resiliency bolstering of key health domains plus targeted interventions for GA-defined deficits. (NCTN: 04914338)
Methods: In this single-institution feasibility study, patients aged ≥65 years planning HCT underwent comprehensive GA followed by MDT outpatient coordinated intervention comprised of six disciplines: hematology/HCT, geriatrics (Geri), physical therapy (PT), dietician, social work (SW), and infectious disease (ID). All patients received standardized interventions for resiliency bolstering in the domains of comorbidities, functional status, emotional health, social support, cognition, nutrition, medication review, advance directives, and care coordination. Patients with a GA-identified deficits additionally received targeted interventions (e.g., PT and geri address falls, Geri deprescribe for polypharmacy). The primary endpoint was feasibility of ≥90% of enrolled participants completing GA and coordinated consultations by ≥4 of 6 MDT disciplines prior to conditioning. In a secondary analysis, disability-free survival (a composite of mobility dependence, falls, delirium, or ICU admission) was compared 1:2 against a propensity-score-matched historical cohort within 30 days of HCT.
Results:
Forty patients were enrolled (median age 72, range 65–80). Among these, 42.5% and 27.5% were pre-frail or frail by the Fried Frailty Index. The primary feasibility endpoint was met: 37 of 40 patients (92.5%) were seen by ≥4 of 6 specialists, preceded by GA. MDT discipline attendance was: HCT 100%, Geri 97.5%, PT 90%, Dietician 82.5%, SW 80%, and ID 75%. Protocol-defined pre-HCT resiliency-bolstering metrics were completed at 75–100% for most measures. Most patients had GA-identified targetable deficits (n=36, 90%). Pre-HCT targeted-intervention completion success varied, ranging from 100% (hearing loss, falls, thin social support, weight loss) to as low as 10.0% for impaired function (requiring PT follow-up in one week) and 10.5% for depression/anxiety/distress. Among the 36 (90%) that proceeded to HCT, median age was 72 years (range 65-80), AML/MDS was the main indication, 83% had matched unrelated donors, 69% received fludarabine-melphalan conditioning and median HCT-comorbidity index score was 3 (interquartile range 1-5). Of these, 26 (72.2%) achieved adequate dose intensity of resiliency bolstering and targeted intervention (pre-specified as ≥11 of 16 process metrics). Disability-free survival at day +30 was 53% in MDT versus 54% in controls (p = 0.91). Disabilities were lower in MDT vs control for delirium (11.1% vs 33.3%, p=0.018) with non-significant reductions in mobility disability (30.6% vs 44.9%, p=0.21), and ICU admission (5.6% vs 14.5%, p=0.21) with similar fall rates (13.9% vs 13%, p=1.0), respectively. One-year NRM was 22.2% for the MDT cohort vs 24.6% for control.
Conclusion: A prospectively defined GA-informed peri-HCT MDT intervention was feasible in older patients. Protocol specified resiliency bolstering was consistently delivered by the MDT, though GA-targeted intervention completion varied by deficit, highlighting challenges of a process for deficit remediation within a short window pre-HCT. Compared to matched historical controls, the MDT cohort experienced similar incidence of disability events although lower rates of delirium and qualitatively lower mobility dependence and ICU admissions. The trial provides a scalable intervention and novel patient-centric endpoints for further testing in prospective randomized trials of older adult HCT.
DISCLOSURES
Lauren G Tagliaferro Epler, MD: No relevant conflicts of interest to declare.